DBV Technologies SA (DBVT)

9.43
0.11 1.18
NASDAQ : Health Technology
Prev Close 9.32
Open 9.45
Day Low/High 9.35 / 9.48
52 Wk Low/High 6.63 / 13.49
Volume 136.99K
Avg Volume 414.50K
Exchange NASDAQ
Shares Outstanding 103.13M
Market Cap 1.03B
EPS -3.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Trading Notes on 21 Stocks I Currently Own

Trading Notes on 21 Stocks I Currently Own

Here are my takes on stocks in biotech and other companies I own right now.

I'm Seeing Quite a Bit of Good Action in Individual Stocks

I'm Seeing Quite a Bit of Good Action in Individual Stocks

The bulls are hoping that this dead cat bounce transitions into a V-shaped bounce.

My Stock of the Week Is Aimmune Therapeutics

My Stock of the Week Is Aimmune Therapeutics

AIMT has developed a 'desensitivity' treatment for peanut allergies.

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

The stock's decline with the sector has occurred despite a steady supply of positive news.

Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

These Stocks Are Trending Up With Monster Volume

These Stocks Are Trending Up With Monster Volume

Let's take a look at several stocks that are experiencing unusual volume activity.